Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0
1

Year Published

2018
2018
2021
2021

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 38 publications
0
9
0
1
Order By: Relevance
“…13 Low-dose supplementation with larginine improved liver function, oxidative stress, nitric oxide metabolite levels, cardiovascular dysfunction, and sickle cell-related pain. 25 CACNA1H is associated with hypertension and is therapeutically targetable by calcium channel blockers. 26 Thus, our findings using sequence analysis of African SCA patients has support from prior studies.…”
Section: Discussionmentioning
confidence: 99%
“…13 Low-dose supplementation with larginine improved liver function, oxidative stress, nitric oxide metabolite levels, cardiovascular dysfunction, and sickle cell-related pain. 25 CACNA1H is associated with hypertension and is therapeutically targetable by calcium channel blockers. 26 Thus, our findings using sequence analysis of African SCA patients has support from prior studies.…”
Section: Discussionmentioning
confidence: 99%
“…SCCRIP is a contemporary natural history cohort study of SCD that provides data on disease progression, education outcomes, and healthcare utilization throughout the lifespan of patients with SCD, some exposed to current and future disease‐modifying therapies, such as the newly approved L‐glutamine . The detailed and standardized characterization of the disease phenotype in SCCRIP, coupled with future genetic, socio‐environmental‐behavioral, and proteomic studies will be a unique resource for advancing the understanding of SCD.…”
Section: Discussionmentioning
confidence: 99%
“…SCCRIP is a contemporary natural history cohort study of SCD that provides data on disease progression, education outcomes, and healthcare utilization throughout the lifespan of patients with SCD, some exposed to current and future disease-modifying therapies, such as the newly approved L-glutamine. [82][83][84] The detailed and standardized char-…”
Section: Discussionmentioning
confidence: 99%
“…24 Renal failure, in particular, and hepatic dysfunction may underlie this association. 25,26 Of note, there were 3 deaths in the L-glutamine arms (but none in the placebo arms) of the 2 randomized trials in SCA that were not deemed by the investigators to be related to L-glutamine. 14,20 Limited clinical information is published only for the individual in the phase 2 trial who died of "multiorgan failure unrelated to study medication."…”
Section: Mechanism Of Action Dosing and Pricementioning
confidence: 99%